Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Ann Thorac Surg. 2021 May;111(5):1465-1471. doi: 10.1016/j.athoracsur.2020.06.120. Epub 2020 Sep 16.
In the era of antiretroviral therapy, HIV-positive patients have reduced mortality from HIV infection and increased morbidity from end-stage heart failure. The number of HIV-positive heart transplantation recipients remains scant. Long-term survival has not been rigorously studied. We compared survival outcomes of heart transplantation in HIV-positive recipients with those of HIV-negative recipients.
Clinical data from all adult heart transplantations were extracted from the United Network for Organ Sharing dataset. The impact of recipient HIV status was analyzed with Cox proportional hazards modeling, 1:3 propensity score matching, and Kaplan-Meier survival analysis.
Seventy-five HIV-positive recipients and 29,848 HIV-negative recipients were identified. Race distributions differed between the recipient groups, with black patients comprising a larger proportion of the HIV-positive recipient group (46.7% vs 20.9%, P < .001). The mean year of transplant was significantly later in the HIV-positive recipient group. The rate of acute rejection in the HIV-positive group was higher than in the HIV-negative group (38.7% vs 17.7%, P < .001), as was rate of antirejection treatment administration such as intravenous immunoglobulin or plasmapheresis (26.7% vs 10.4%, P < .001). There was no difference in 30-day, 1-year, and 5-year survival of HIV-positive recipients vs HIV-negative recipients. Recipient HIV infection was not a significant covariate in predicting survival in a Cox proportional hazards model.
Short-term and moderate-term survival after heart transplantation is similar for HIV-positive recipients and HIV-negative recipients, although data are very limited. This finding suggests that HIV-positive recipients should not be excluded from transplant candidacy solely based on HIV serostatus.
在抗逆转录病毒疗法时代,HIV 阳性患者因 HIV 感染导致的死亡率降低,而因终末期心力衰竭导致的发病率增加。HIV 阳性心脏移植受者的数量仍然很少。长期生存情况尚未得到严格研究。我们比较了 HIV 阳性受者和 HIV 阴性受者心脏移植的生存结果。
从美国器官共享网络(United Network for Organ Sharing)数据集提取所有成人心脏移植的临床数据。使用 Cox 比例风险模型、1:3 倾向评分匹配和 Kaplan-Meier 生存分析来分析受者 HIV 状态的影响。
确定了 75 名 HIV 阳性受者和 29,848 名 HIV 阴性受者。受者组之间的种族分布不同,黑人患者在 HIV 阳性受者组中占比更大(46.7%比 20.9%,P <.001)。HIV 阳性受者组的平均移植年份明显较晚。HIV 阳性组的急性排斥反应发生率高于 HIV 阴性组(38.7%比 17.7%,P <.001),抗排斥治疗的使用率(如静脉注射免疫球蛋白或血浆置换)也更高(26.7%比 10.4%,P <.001)。HIV 阳性受者与 HIV 阴性受者的 30 天、1 年和 5 年生存率无差异。在 Cox 比例风险模型中,受者 HIV 感染不是预测生存的重要协变量。
HIV 阳性受者与 HIV 阴性受者心脏移植后的短期和中期生存相似,尽管数据非常有限。这一发现表明,不应仅基于 HIV 血清学状况将 HIV 阳性受者排除在移植候选者之外。